The Food and Drug Administration on Tuesday approved Gilead Sciences' hepatitis C treatment Vosevi.
Vosevi is intended as a follow-up treatment for adults with chronic hepatitis C virus genotypes 1 through 6 who have mild or no cirrhosis.
The fixed-dose combination tablet combines Gilead's two previously approved hepatitis C treatments Sovaldi and Epclusa, along with a new drug, voxilaprevir.
More articles on supply chain:
Herbal coffee recalled for containing erectile dysfunction drug ingredien
Puma Biotech earns FDA approval for breast cancer drug
A supply chain expert on what your performance dashboard is missing